Diabetes, anemia and ckd: Why treat?

Current Diabetes Reports

Volumn 10, Issue 4, 2010, Pages 291-296

  Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; CKD; CREATE; Diabetes mellitus; Epoetin; Erythropoiesis stimulating agent; Erythropoietin; ESA; TREAT. CHOIR

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANEMIA; ARTERY EMBOLISM; ARTERY THROMBOSIS; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG SAFETY; HUMAN; MEDICAL DECISION MAKING; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; REVIEW; RISK ASSESSMENT; STROKE; TREATMENT INDICATION; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; ANALOGS AND DERIVATIVES; COMPLICATION; DIABETES MELLITUS, TYPE 2; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA; DIABETES MELLITUS, TYPE 2; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 77956395473     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0123-5     Document Type: Review

References (24)

1. US Renal Data System: United States Renal Data System Annual Data Report. Am J Kid Dis 2007, 49(Suppl 1):S10-S294. This reference provides extensive analysis of the definitive ESRD registry in the United States. It provides data tables and figures on the epidemiology of dialysis and its complications. In particular, it makes the point that diabetes is the most common cause of ESRD.
2. Williams ME: Diabetic CKD/ESRD 2010: A Progress Report? Semin Dial 2010 Feb 22 [Epub ahead of print]. Williams discusses the progress and some of the challenges in diabetic CKD and ESRD-diagnosis and treatment.
3. Astor BC, Muntner P, Levin A, et al.: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002, 162:1401-1408.
4. Vlagopoulos PT, Tighiouart H, Weiner DE, et al.: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005, 16:3403-3410.
5. McFarlane SI, Salifu MO, Makaryus J, Sowers JR: Anemia and cardiovascular disease in diabetic nephropathy. Curr Diab Rep 2006, 6:213-218.
6. McCullough PA, Lepor NE: The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 2005, 6(1):1-10.
7. McClellan WM: Epidemiology and risk factors for chronic kidney disease. Med Clin North Am 2005, 89:419-445.
8. Keane WF, Lyle PA: Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study. Am J Kidney Dis 2003, 41(3 Suppl 1):S22-S25.
9. PROCRIT (Epoetin alfa) FOR INJECTION. Available at http://www. accessdata.fda.gov/drugsatfda-docs/label/2007/103234s5158lbl.pdf. Accessed May 2010.
10. Pfeffer MA, Burdmann EA, Chen CY, et al.: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009, 361:2019-2032. This is the primary report of the landmark TREAT study. The findings are discussed in detail in the current paper.
11. Singh AK: Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol 2010, 21:2-6. In this article, Singh reviews the evidence from recent trials and makes recommendations for clinical nephrologists for treating anemia using ESAs in nondialysis CKD patients.
12. Del Vecchio L: The results of the TREAT study: lessons and limitations [in Italian]. G Ital Nefrol 2010, 27:3. Del Vecchio reviews the findings of the TREAT study and is critical of its design and conclusions.
13. Alcázar R, Tato A, García F, et al.: Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study? [in Spanish]. Nefrologia 2010, 30:114-18. Alcázar et al. argue that despite the findings of the TREAT study, no change in management of CKD anemia with ESAs is necessary.
14. de Francisco AL, Aljama P, Arias M, et al.: Anaemia correction in diabetic patients with chronic kidney disease without substitutive treatment: teachings from TREAT study [in Spanish]. Nefrologia 2010, 30:15-20. de Francisco et al. review the TREAT study, particularly its strength as a placebo-controlled study, although the rescue feature in the placebo arm concerns the authors that TREAT was not truly placebo controlled.
15. Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584-590.
16. Drueke TB, Locatelli F, Clyne N, et al.: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006, 355:2071-2084.
17. Singh AK, Szczech L, Tang KL, et al.: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006, 355:2085-2098.
18. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125:605-613.
19. Prentice RL: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
20. KDOQI; National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006, 47:S16-S85.
21. Bennett CL, Silver SM, Djulbegovic B, et al.: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008, 299:914-924. Bennett et al. present a meta-analysis that reports heightened risk of mortality and thromboembolism in cancer patients treated with ESAs. The meta-analysis has been influential in raising concerns among oncologists and the FDA regarding the safety of ESAs.
22. Stowell CP, Jones SC, Enny C, et al.: An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976) 2009, 34:2479-2485. This multicenter RCT shows that in relatively healthy patients undergoing orthopedic spine surgery, exposure to ESA was associated with a higher risk of thromboembolism. This study has been cited by the FDA in its safety review of ESAs.
23. Corwin HL, Gettinger A, Fabian TC, et al.: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007, 357:965-976.
24. Wright RJ, Kanagasundaram NS, Quinton R, et al.: Darbepoetin alfa and chronic kidney disease. N Engl J Med 2010, 362:653; author reply 655.